U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C5H9NO3S
Molecular Weight 163.1961
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIOPRONIN

SMILES

CC(C(=NCC(=O)O)O)S

InChI

InChIKey=YTGJWQPHMWSCST-UHFFFAOYSA-N
InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C5H9NO3S
Molecular Weight 163.1961
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: https://en.wikipedia.org/wiki/Tiopronin

Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output. Tiopronin is a chelating agent. It works by removing extra cystine (the cause of kidney stones) from the urine, which keeps the kidney stones from forming. It works by reacting with urinary cysteine to form a more soluble, disulfide linked, tiopronin-cysteine complex.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THIOLA

Approved Use

Tiopronin

Launch Date

594950400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.6 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIOPRONIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIOPRONIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.7 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIOPRONIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 g 3 times / day multiple, oral
Highest studied dose
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43-74
Health Status: unhealthy
Age Group: 43-74
Sex: M+F
Sources:
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
Health Status: unhealthy
Age Group: 56.7
Sex: M+F
Sources:
Other AEs: Proteinuria, Stomatitis...
Other AEs:
Proteinuria (4 patients)
Stomatitis (3 patients)
Itching (2 patients)
Discomfort epigastric (1 patient)
Sources:
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2%)
Nausea (25%)
Emesis (10%)
Diarrhea (18%)
Abdominal pain
Oral ulceration (12%)
Fever (8%)
Weakness (4%)
Fatigue (14%)
Edema peripheral (6%)
Chest pain
Anorexia (8%)
Arthralgia
Proteinuria (10%)
Impotence
Cough
Rash (14%)
Ecchymosis (6%)
Pruritus (4%)
Urticaria (8%)
Skin wrinkling (6%)
Sources:
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (6%)
Nausea (12%)
Emesis
Diarrhea (6%)
Abdominal pain (6%)
Oral ulceration (18%)
Fever
Weakness (12%)
Fatigue
Edema peripheral (6%)
Chest pain (6%)
Anorexia
Arthralgia (12%)
Proteinuria (6%)
Impotence (6%)
Cough (6%)
Rash (12%)
Ecchymosis
Pruritus (6%)
Urticaria
Skin wrinkling (6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Discomfort epigastric 1 patient
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
Health Status: unhealthy
Age Group: 56.7
Sex: M+F
Sources:
Itching 2 patients
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
Health Status: unhealthy
Age Group: 56.7
Sex: M+F
Sources:
Stomatitis 3 patients
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
Health Status: unhealthy
Age Group: 56.7
Sex: M+F
Sources:
Proteinuria 4 patients
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
Health Status: unhealthy
Age Group: 56.7
Sex: M+F
Sources:
Abdominal pain
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Arthralgia
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Chest pain
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Cough
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Impotence
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Emesis 10%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Proteinuria 10%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Oral ulceration 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Fatigue 14%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Rash 14%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Diarrhea 18%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Anemia 2%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Nausea 25%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Pruritus 4%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Weakness 4%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Ecchymosis 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Edema peripheral 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Skin wrinkling 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Anorexia 8%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Fever 8%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Urticaria 8%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Anorexia
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Ecchymosis
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Emesis
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Fatigue
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Fever
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Urticaria
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Arthralgia 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Nausea 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Rash 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Weakness 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Oral ulceration 18%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Abdominal pain 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Anemia 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Chest pain 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Cough 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Diarrhea 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Edema peripheral 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Impotence 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Proteinuria 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Pruritus 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Skin wrinkling 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Meprin proteolytic complexes at the cell surface and in extracellular spaces.
2003
Enhancement of antiradiation potential of some aminothiols by beta-carotene.
2003
[An observation of the effects of Tiopronin on the oxygen free radicals in severely scalded rats receiving delayed fluid resuscitation].
2003 Apr
Mitochondrial adenosine triphosphate-regulated potassium channel opening acts as a trigger for isoflurane-induced preconditioning by generating reactive oxygen species.
2003 Apr
Studies of urinary cystine precipitation in vitro: ontogeny of cystine nephrolithiasis and identification of meso-2,3-dimercaptosuccinic acid as a potential therapy for cystinuria.
2003 Dec
Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds.
2003 Dec
Au nanoparticle-enhanced surface plasmon resonance sensing of biocatalytic transformations.
2003 Dec 15
A simple and sensitive chemiluminescence method for the determination of tiopronin for a pharmaceutical formulation.
2003 Dec 4
[Long-term study of tiopronin in patients with cystinuria].
2003 Feb
Involvement of reactive oxygen species in cardiac preconditioning in rats.
2003 Feb
Effects of N-(2-mercaptopropionyl)-glycine on mitochondrial function in ischemic-reperfused heart.
2003 Feb
The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart.
2003 Feb
Possible underlying mechanism for hydrogen peroxide-induced electromechanical suppression in human atrial myocardium.
2003 Jan
Effects of sulfhydryl compounds on pancreatic cytoprotection in acute necrotic pancreatitis.
2003 Jan
Paradoxical effects of thiol reagents on Jurkat cells and a new thiol-sensitive mutant form of human mitochondrial superoxide dismutase.
2003 Jan 1
Modifications of myosin-regulatory light chain correlate with function of stunned myocardium.
2003 Jul
Cystine crystal volume determination: a useful tool in the management of cystinuric patients.
2003 Jul
Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors.
2003 Jul
Protective effect of N2-mercaptopropionylglycine on rats and dogs liver during ischemia/reperfusion process.
2003 Jul-Sep
Oxygen dependency of the adrenergic Na/H exchange in rainbow trout erythrocytes is diminished by a hydroxyl radical scavenger.
2003 Jun
[Cystinuria - Cystine Stones: Recommendations for Diagnosis, Therapy and Follow-up].
2003 Mar
Cardiac ischemia causes inhibition of the Na/K ATPase by a labile cytosolic compound whose production is linked to oxidant stress.
2003 Mar 15
Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy.
2003 Nov
The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K(+)(ATP) channels, and the production of reactive oxygen species.
2003 Nov
Cardiac nerves affect myocardial stunning through reactive oxygen and nitric oxide mechanisms.
2003 Oct 31
Heterophase ligand exchange and metal transfer between monolayer protected clusters.
2003 Sep 24
Exogenous nitric oxide generates ROS and induces cardioprotection: involvement of PKG, mitochondrial KATP channels, and ERK.
2004 Apr
Polyherbal extract of septilin protects mice against whole body lethal dose of gamma radiation.
2004 Aug
Yellow nail syndrome in rheumatoid arthritis: a drug-induced disease?
2004 Aug
Exogenous NO triggers preconditioning via a cGMP- and mitoKATP-dependent mechanism.
2004 Aug
Transport of meprin subunits through the secretory pathway: role of the transmembrane and cytoplasmic domains and oligomerization.
2004 Aug 13
Delayed ischemic preconditioning activates nuclear-encoded electron-transfer-chain gene expression in parallel with enhanced postanoxic mitochondrial respiratory recovery.
2004 Aug 3
Liquid chromatography analysis of N-(2-mercaptopropionyl)-glycine in biological samples by ThioGlo 3 derivatization.
2004 Aug 5
Remote preconditioning by infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in the rat heart.
2004 Feb 15
Activation of mitochondrial ATP-sensitive potassium channels delays ischemia-induced cellular uncoupling in rat heart.
2004 Jan
Delayed cardioprotection is mediated via a non-peptide delta opioid agonist, SNC-121, independent of opioid receptor stimulation.
2004 Jan
Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection.
2004 Jan
Oligonucleotide-displaced organic monolayer-protected silver nanoparticles and enhanced luminescence of their salted aggregates.
2004 Jul 1
The MAM (meprin/A5-protein/PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase mu.
2004 Jun 25
Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection.
2004 Mar
ROS-mediated ERK activation in delayed protection from anoxic preconditioning in neonatal rat cardiomyocytes.
2004 Mar
Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts.
2004 Mar
The effects of ionizing radiation on DNA: the role of thiols as radioprotectors.
2004 Mar 26
Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity.
2004 May
The role of antioxidants in protection from ototoxic drugs.
2004 May
Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors.
2004 May
Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin c in small cell lung cancer cells.
2004 Nov 1
HPLC study of tyrosinase inhibition by thiopronine.
2004 Sep
Complexation of polysaccharide and monosaccharide with thiolate boronic acid capped on silver nanoparticle.
2004 Sep 15
Nanoparticles comprising a mixed monolayer for specific bindings with biomolecules.
2004 Sep 29
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Urinary cystine should be measured at 1 month after THIOLA treatment, and every 3 months thereafter. THIOLA dosage should be readjusted depending on the urinary cystine value.
THIOLA (Tiopronin) may be begun at a dosage of 800 mg/day in adult patients with cystine stones. In a multiclinic trial, average dose of THIOLA was about 1000 mg/day. In children, initial dosage may be based on 15 mg/kg/day. Whenever possible, THIOLA should be given in divided doses 3 times/day at least one hour before or 2 hours after meals.
Route of Administration: Oral
In Vitro Use Guide
Tiopronin (2 mM) completely prevents the Cisplatin-induced increase in enzyme leakage and substantially blocks the decrease of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction caused by Cisplatin. Tiopronin also significantly protects the renal slices from cisplatin-induced toxic effects. Tiopronin protects against cisplatin-induced nephrotoxicity by acting as an alternative target for Cisplatin both intra- and extracellularly and thus protects against cisplatin-induced depletion of glutathione in the kidney cell
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:33:59 UTC 2021
Edited
by admin
on Fri Jun 25 20:33:59 UTC 2021
Record UNII
C5W04GO61S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIOPRONIN
INN   JAN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
NSC-760416
Code English
MERCAPTOPROPIONYLGLYCINE
Systematic Name English
MERCAPTOPROPIONYLGLYCINE-
Systematic Name English
GLYCINE, N-(2-MERCAPTO-1-OXOPROPYL)-
Systematic Name English
THIOLA EC
Brand Name English
THIOLA
Brand Name English
TIOPRONIN [JAN]
Common Name English
TIOPRONIN [MI]
Common Name English
TIOPRONIN [ORANGE BOOK]
Common Name English
TIOPRONIN [INN]
Common Name English
TIOPRONIN [VANDF]
Common Name English
TIOPRONINE
Common Name English
TIOPRONIN [MART.]
Common Name English
TIOPRONIN [WHO-DD]
Common Name English
N-(2-MERCAPTOPROPIONYL)GLYCINE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 12386
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
NCI_THESAURUS C78275
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
NDF-RT N0000175898
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
NDF-RT N0000011378
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
WHO-VATC QR05CB12
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
NDF-RT N0000175549
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
WHO-ATC G04BX16
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
NDF-RT N0000011378
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
WHO-ATC R05CB12
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
WHO-VATC QG04BC90
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C47758
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
PUBCHEM
5483
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
INN
3574
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
MERCK INDEX
M10879
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY Merck Index
CAS
1953-02-2
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
ChEMBL
CHEMBL1314
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
WIKIPEDIA
TIOPRONIN
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
EVMPD
SUB11089MIG
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
FDA UNII
C5W04GO61S
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
RXCUI
6765
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY RxNorm
MESH
D008625
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
DRUG CENTRAL
2676
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
DRUG BANK
DB06823
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
EPA CompTox
1953-02-2
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
ECHA (EC/EINECS)
217-778-4
Created by admin on Fri Jun 25 20:34:00 UTC 2021 , Edited by admin on Fri Jun 25 20:34:00 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY